ClinicalTrials.gg
Not yet recruitingNCT06234670Updated Jan 31, 2024

Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids

An observational study in Uterine Fibroid and Recurrence, sponsored by Wenwen Wang. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by Wenwen Wang · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,200
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
2nd of 11
3,200 · median 200
Started
2024
with 3 others
Observational
11 of 40
8 open now
Primary completion
2025-01
later than 2 of 22 live
Registered
22nd of 40
by date
Lead sponsor
3 of 40
Wenwen Wang

Among the 40 studies in Leiomyoma with a site in China, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2024, is one of 11 observational ones, reaches primary completion later than 2 of the 22 other live ones, and was the 22nd registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

To research risk factors for recurrence of uterine fibroids and build a prediction model of recurrence of uterine fibroids to facilitate the early detection as well as the early intervention for patients who are prone to recur.

Read the detailed description

Uterine fibroids are the most common benign tumors of female reproductive organs during childbearing age. With the emphasis on fertility preservation and the pursuit of the physical integrity, about 46% of patients prefer the conservative surgery which preserves the uterus. However, the high recurrence rate of uterine fibroids after conservative surgery does cause formidable clinical problems.

According to the literature, the recurrence rate is about 11.7% at one year after myomectomy and would increase steadily. At the eighth year of myomectomy, the recurrence rate is as high as 84.4%. During the long-term follow-up, about one-third of patients eventually require reoperation.

Recurrence not only leads to the recurrence of fibroid-related symptoms such as anemia, abdominal and pelvic pain, frequent urination and urgency, abnormal stool, etc., but also increases the burden of economic and national medical insurance, besides, it even causes serious problems such as psychological disorders, infertility, adverse pregnancy outcomes and malignant transformation, which affecting physical and mental health as well as destroying family happiness and threatening national population security.

03

Conditions studied

  • Uterine Fibroid
  • Recurrence

Keywords

  • Uterine Fibroid
  • Recurrence
  • Risk factor
  • Prediction medel
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Female patients with uterine fibroids and accept myomectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age:18-50 years
  2. Diagnosed with uterine fibroids (by ultrasound or pathology)
  3. Accept myomectomy.
  4. Complete clinical data.

Exclusion criteria

Exclusion Criteria:

  1. Severe infectious disease
  2. Previous history of malignant tumors
  3. Incomplete clinical data.
  4. Pregnant
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with uterine fibroids accepted myomectomy.

    Complete the observation and follow-up, to identify the outcome (recur or not recur).

    Other: No intervertion

Interventions

  • OtherNo intervertion

    This study is a retrospective observational study without intervention.

06

What researchers measure

Primary outcomes

  1. The performance of the prediction model for recurrence of uterine fibroids as assessed by AUC

    Complete the follow-up, and compare the actual recurrence population with the predicted recurrence population to judge the performance of the prediction model. Use the AUC (Area Under Curve)

    Time frame: through study completion, about June.2025

Secondary outcomes

  1. Numbers of risk factors of recurrent uterine fibroids as certained by statistic analysis

    To identify the risk factors of recurrent uterine fibroids. We identify the risk factors through statistic analysis. Statistical significance proves to be the symbol of identifycation of risk factors.

    Time frame: about June.2024

  2. The recurrence rate of uterine fibroids yearly

    To calculate the recurrence rate of uterine fibroids yearly

    Time frame: about Febrary.2024

  3. The fertility rate after myomectomy

    To research the fertility rate after myomectomy and evaluate the impact of the surgery.

    Time frame: about Febrary.2024

  4. The quality of life after myomectomy will be assessed by UFS-QOL,(uterine fibroid symptom and health-related quality of life, UFS-QOL)

    To assess the quality of life after myomectomy, we use UFS-QOL.The UFS-QOL, the most popular self-administered instrument in assessing the whole spectrum of fibroid-related symptoms and health-related quality of life among patients with uterine fibroids, was designed in 2002s by James B et.al. Consisting of eight symptom items and twenty-nine health-related quality of life (HRQL) items of six subscales (concern, activities, energy/mood, control, self-consciousness, and sexual functioning), UFS-QOL is scored with a 5-point scale which demonstrates the patient' state of past 3 months. The final score (range, 0-100) is transformed based on a specific formula. Usually, a higher symptom severity score means more severe symptoms while a higher HRQL score indicates more perfect health

    Time frame: through study completion, about June.2025

  5. The degree of abdominal pain after myomectomy will be assessed by VAS(visual analogue scale, VAS)

    VAS is the most commonly used one-dimensional measure of pain intensity. The scale consists mainly of a 100 mm straight line with one end indicating "completely painless" and the other end indicating "the most severe pain imaginable" or "extremely painful", etc. Patients will be asked to mark the line at the appropriate location to represent the intensity of the pain they are experiencing at the time

    Time frame: through study completion, about June.2025

  6. The blood loss will be assessed by PBLAC (Pictorial Blood Loss Assessment Chart (PBLAC)

    The Pictorial Blood Loss Assessment Chart (PBLAC) proposed by Higham JM in 1990 is widely used internationally to evaluate menstrual flow. 1 Menstrual blood loss chart The menstrual blood loss chart is given different scores according to the different degrees of blood staining of each sanitary napkin: mild (1 point), the blood stained area \< 1/3 of the whole sanitary napkin; Moderate (5 points): The blood stained area accounts for 1/3\~3/5 of the whole sanitary napkin; Severe (20 points): The blood-stained area is basically the entire sanitary napkin.

    Time frame: through study completion, about June.2025

07

Study locations

1 site
  • Shixuan Wang
    Wuhan, None Selected 430030, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Jan 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 31, 2024
StartEst.
Jan 25, 2024
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2025
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06234670
Lead sponsor
Wenwen Wang
Collaborators
Tongji Hospital
Responsible party
Wenwen Wang (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Jan 31, 2024
Start date
Jan 25, 2024 (estimated)
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Jan 31, 2024

Study contacts

shixuan Wang, Phd
Contact
shixuanwang@tjh.tjmu.edu.cn
86-27-83663078
Wenwen Wang, Phd
Contact
wenwenwang@hust.edu.cn
86-27-83663078
Shixuan Wang, Phd
study chair · Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion